The average one-year price target for Co-Diagnostics (NasdaqCM:CODX) has been revised to $38.25 / share. This is an increase ...

SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...

SALT LAKE CITY, March 6, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of ...

Co-Diagnostics, Inc. announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City, where it will connect with institutional investors and showcase ...

SALT LAKE CITY, Jan. 30, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of ...

Co-Diagnostics (NASDAQ:CODX) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Co-Diagnostics to ...

For over 100 years, The Union World Conference on Lung Health has come together to present the latest scientific research in all aspects of lung health. This year's event falls shortly after the ...

SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular ...

SALT LAKE CITY, Sept. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...